- Histogen Inc HSTO, and its partner Amerimmune LLC, have announced topline results from its Phase 1 study evaluating emricasan in mild symptomatic COVID-19 patients.
- The study demonstrated that emricasan was safe and well-tolerated during the 14 days of dosing and at the day 45 follow-up compared to placebo with no reports of serious adverse events.
- Patients who completed treatment with emricasan had a complete resolution of the symptoms most commonly associated with mild COVID-19, such as cough, headache, and fatigue, at day seven and continued through day 45.
- Patients in the placebo arm who completed the study did not experience COVID-19 symptom resolution until the 45th day.
- Price Action: HSTO shares are up 9.8% at $1.04 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
